Gupta, V. K., Giri, R. and Agrawal, S. (2021) “Dipeptidyl peptidase-4 inhibitor (teneligliptin) significantly reduces liver fat content and delays progression of non-alcoholic steatohepatitis in type 2 diabetes mellitus patients”, International Journal of Advances in Medicine, 8(12), pp. 1817–1820. doi: 10.18203/2349-3933.ijam20214516.